On Thursday, Dec. 19, the U.S. Food and Drug Administration announced in a statement that after two years of being in shortage, tirzepatide — the active ingredient in Zepbound and its counterpar ...

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...

Consumers who take copies of the popular weight loss and diabetes drug tirzepatide will likely need to find a new source for these medications early next year. On Thursday, the Food and Drug ...

Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says. Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025 ...

Tirzepatide is approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, alongside diet and exercise. The SURMOUNT-OSA trial showed significant reductions in breathing ...

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...

The FDA announced that the tirzepatide injection shortage is resolved. Hims & Hers Health, Inc.'s stock fell 6.90%, reflecting market concerns over regulatory updates and supply chain stability.

The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s popular diabetes and weight-loss drugs Mounjaro and Zepbound ...